Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Financial conflicts of interest are common in the drug industry. Photo: Wodicka/ullstein bild via Getty Images
An analysis by the publication Science has "found widespread after-the-fact payments or research support" from pharmaceutical companies to expert officials who advised the Food and Drug Administration to approve those companies' drugs.
Why it matters: Conflicts of interest are common in the health care industry, especially between companies that make drugs and doctors who prescribe them. But this new analysis indicates people who sit on official government panels, and who are supposed to evaluate drugs impartially, are getting rewarded later from the drug companies they helped.